Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 164

Cited In for PubMed (Select 2408149)

1.

Oncogene addiction: pathways of therapeutic response, resistance, and road maps toward a cure.

Pagliarini R, Shao W, Sellers WR.

EMBO Rep. 2015 Mar;16(3):280-296. Epub 2015 Feb 13. Review.

PMID:
25680965
2.

Inhibition of Aurora kinase B is important for biologic activity of the dual inhibitors of BCR-ABL and Aurora kinases R763/AS703569 and PHA-739358 in BCR-ABL transformed cells.

Illert AL, Seitz AK, Rummelt C, Kreutmair S, Engh RA, Goodstal S, Peschel C, Duyster J, von Bubnoff N.

PLoS One. 2014 Nov 26;9(11):e112318. doi: 10.1371/journal.pone.0112318. eCollection 2014.

3.

Two decades of leukemia oncoprotein epistasis: the MLL1 paradigm for epigenetic deregulation in leukemia.

Li BE, Ernst P.

Exp Hematol. 2014 Dec;42(12):995-1012. doi: 10.1016/j.exphem.2014.09.006. Epub 2014 Sep 28. Review.

PMID:
25264566
4.

Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms.

Chen X, Shi X, Zhao C, Li X, Lan X, Liu S, Huang H, Liu N, Liao S, Zang D, Song W, Liu Q, Carter BZ, Dou QP, Wang X, Liu J.

Oncotarget. 2014 Oct 15;5(19):9118-32.

5.

Inhibition of euchromatic histone methyltransferase 1 and 2 sensitizes chronic myeloid leukemia cells to interferon treatment.

Loh SW, Ng WL, Yeo KS, Lim YY, Ea CK.

PLoS One. 2014 Jul 31;9(7):e103915. doi: 10.1371/journal.pone.0103915. eCollection 2014.

6.

Imatinib: a breakthrough of targeted therapy in cancer.

Iqbal N, Iqbal N.

Chemother Res Pract. 2014;2014:357027. doi: 10.1155/2014/357027. Epub 2014 May 19. Review.

7.

Safety of bosutinib versus imatinib in the phase 3 BELA trial in newly diagnosed chronic phase chronic myeloid leukemia.

Gambacorti-Passerini C, Cortes JE, Lipton JH, Dmoszynska A, Wong RS, Rossiev V, Pavlov D, Gogat Marchant K, Duvillié L, Khattry N, Kantarjian HM, Brümmendorf TH.

Am J Hematol. 2014 Oct;89(10):947-53. doi: 10.1002/ajh.23788. Epub 2014 Jul 21.

8.

Influence of oncogenic transcription factors on chromatin conformation and implications in prostate cancer.

Yang YA, Kim J, Yu J.

Appl Clin Genet. 2014 May 12;7:81-91. doi: 10.2147/TACG.S35598. eCollection 2014. Review.

9.

Current concepts in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia.

Bernt KM, Hunger SP.

Front Oncol. 2014 Mar 25;4:54. doi: 10.3389/fonc.2014.00054. eCollection 2014. Review.

10.

The aurora kinases in cell cycle and leukemia.

Goldenson B, Crispino JD.

Oncogene. 2015 Jan 29;34(5):537-45. doi: 10.1038/onc.2014.14. Epub 2014 Mar 17. Review.

PMID:
24632603
11.

PTEN regulates BCRP/ABCG2 and the side population through the PI3K/Akt pathway in chronic myeloid leukemia.

Huang FF, Zhang L, Wu DS, Yuan XY, Yu YH, Zhao XL, Chen FP, Zeng H.

PLoS One. 2014 Mar 6;9(3):e88298. doi: 10.1371/journal.pone.0088298. eCollection 2014. Erratum in: PLoS One. 2014;9(6):e99917.

12.

Clinical targeting of mutated and wild-type protein tyrosine kinases in cancer.

Drake JM, Lee JK, Witte ON.

Mol Cell Biol. 2014 May;34(10):1722-32. doi: 10.1128/MCB.01592-13. Epub 2014 Feb 24. Review.

13.

Imatinib mesylate resistance and mutations: An Indian experience.

Srivastava S, Dutt S.

Indian J Med Paediatr Oncol. 2013 Jul;34(3):213-20. doi: 10.4103/0971-5851.123748.

14.

Evaluation of the safety of imatinib mesylate in 200 iraqi patients with chronic myeloid leukemia in the chronic phase: single-center study.

Matti BF, Alwan AF, Alwan AF.

Turk J Haematol. 2013 Dec;30(4):387-93. doi: 10.4274/Tjh.2012.0135. Epub 2013 Dec 5.

15.

Turkish Chronic Myeloid Leukemia Study: Retrospective Sectional Analysis of CML Patients.

Sahin F, Saydam G, Cömert M, Uz B, Yavuz AS, Turan E, Yönal I, Atay H, Keltikli E, Turgut M, Pehlivan M, Akay MO, Gürkan E, Paydaş S, Kahraman S, Demirkan F, Kırkızlar O, Akpınar S, Pamuk GE, Demir M, Ozbaş HM, Sönmez M, Gültürk M, Salihoğlu A, Eşkazan AE, Ar C, Haydaroğlu Şahin H, Ongören S, Başlar Z, Aydın Y, Yenere MN, Tüzüner N, Ferhanoğlu B, Haznedaroglu IC, Ilhan O, Soysal T.

Turk J Haematol. 2013 Dec;30(4):351-8. doi: 10.4274/tjh.2013.0151. Epub 2013 Dec 5.

16.

Gambogic acid induces apoptosis in imatinib-resistant chronic myeloid leukemia cells via inducing proteasome inhibition and caspase-dependent Bcr-Abl downregulation.

Shi X, Chen X, Li X, Lan X, Zhao C, Liu S, Huang H, Liu N, Liao S, Song W, Zhou P, Wang S, Xu L, Wang X, Dou QP, Liu J.

Clin Cancer Res. 2014 Jan 1;20(1):151-63. doi: 10.1158/1078-0432.CCR-13-1063. Epub 2013 Dec 12.

17.

Regulatory effects of sestrin 3 (SESN3) in BCR-ABL expressing cells.

Vakana E, Arslan AD, Szilard A, Altman JK, Platanias LC.

PLoS One. 2013 Nov 18;8(11):e78780. doi: 10.1371/journal.pone.0078780. eCollection 2013.

18.

Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus.

Huang ZL, Gao M, Li QY, Tao K, Xiao Q, Cao WX, Feng WL.

Oncotarget. 2013 Dec;4(12):2249-60.

19.

Clonal evolution in hematological malignancies and therapeutic implications.

Landau DA, Carter SL, Getz G, Wu CJ.

Leukemia. 2014 Jan;28(1):34-43. doi: 10.1038/leu.2013.248. Epub 2013 Aug 27. Review.

20.

Bcr-Abl tyrosine kinase inhibitors- current status.

Mughal A, Aslam HM, Khan AM, Saleem S, Umah R, Saleem M.

Infect Agent Cancer. 2013 Jun 20;8(1):23. doi: 10.1186/1750-9378-8-23.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk